Design Therapeutics Inc (DSGN)
Healthcare
Biotechnology
—
12.20 $
-3.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Design Therapeutics Inc (DSGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -54 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -0.1 | -8.7 | -29 | -51 | -59 | -43 | -54 | |
| 0.0 | 0.0 | 0.1 | 0.4 | 0.5 | 0.6 | -2.6 | |
| 0.0 | 0.5 | 4.7 | 11 | 13 | 13 | 15 | |
| 0.1 | 0.4 | 4.7 | 11 | – | – | – | |
| 1.8 | -0.8 | 1.4 | 2.0 | 0.7 | -1.0 | 3.1 | |
| 0.1 | 0.1 | 1.5 | 0.9 | 0.3 | 0.3 | 0.2 | |
| -34 | -34 | -54 | -221 | 53 | 44 | 23 | |
| – | – | 0.2 | 0.3 | 0.3 | 0.5 | 0.6 | |
| 0.2 | -0.2 | 0.0 | -0.4 | – | – | – | |
| 0.2 | 45 | 379 | 0.2 | 0.7 | 0.5 | 26 | |
| 0.1 | 2.3 | 296 | -272 | -5.3 | 1.4 | -5.7 | |
| -0.1 | -8.7 | -31 | -52 | -59 | -43 | -55 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.